Laura R. Marks, MD, PhD

Washington University in St. Louis (WU)

Little is known about the basic pathophysiology of infections in OUD patients, despite the growing epidemic. Patients who develop these life-threatening infections are a unique patient population with high morbidity and mortality. Our lab uses metabolomic approaches to understand the role of the microbiome in xenobiotic transformation of opioid metabolites and the associated risks of both invasive infections and overdose.